![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (S)-nicotine | multiple interactions | ISO | RGD:1552051 | 6480464 | [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... | CTD | PMID:20230807 | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | decreases expression | ISO | RGD:1552051 | 6480464 | 1-Methyl-4-phenyl-1 more ... | CTD | PMID:20230807 | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | multiple interactions | ISO | RGD:1552051 | 6480464 | [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... | CTD | PMID:20230807 | 17beta-estradiol | increases expression | ISO | RGD:1552051 | 6480464 | Estradiol results in increased expression of CLCA2 mRNA | CTD | PMID:19484750 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of CLCA2 mRNA, [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA2 mRNA | CTD | PMID:26496021, PMID:32741896 | 17beta-estradiol | multiple interactions | ISO | RGD:1312594 | 6480464 | [Estradiol co-treated with TGFB1 protein] results in decreased expression of CLCA2 mRNA | CTD | PMID:30165855 | 17beta-estradiol 3-benzoate | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA2 mRNA | CTD | PMID:32741896 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1552051 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CLCA2 mRNA | CTD | PMID:18691609 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CLCA2 mRNA | CTD | PMID:33387578 | 2,5-hexanedione | multiple interactions | EXP | | 6480464 | [carbendazim co-treated with 2, 5-hexanedione] results in decreased expression of CLCA2 mRNA | CTD | PMID:22382377 | aflatoxin B1 | increases expression | ISO | RGD:1312594 | 6480464 | Aflatoxin B1 results in increased expression of CLCA2 mRNA | CTD | PMID:22100608 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of CLCA2 mRNA | CTD | PMID:16483693 | amphetamine | increases expression | EXP | | 6480464 | Amphetamine results in increased expression of CLCA2 mRNA | CTD | PMID:30779732 | arsane | decreases expression | ISO | RGD:1552051 | 6480464 | Arsenic results in decreased expression of CLCA2 mRNA | CTD | PMID:19654921 | arsenic atom | decreases expression | ISO | RGD:1552051 | 6480464 | Arsenic results in decreased expression of CLCA2 mRNA | CTD | PMID:19654921 | arsenous acid | increases expression | ISO | RGD:1312594 | 6480464 | Arsenic Trioxide results in increased expression of CLCA2 mRNA | CTD | PMID:26705709 | benzo[a]pyrene | increases mutagenesis | ISO | RGD:1312594 | 6480464 | Benzo(a)pyrene results in increased mutagenesis of CLCA2 gene | CTD | PMID:25435355 | benzo[a]pyrene | increases expression | ISO | RGD:1312594 | 6480464 | Benzo(a)pyrene results in increased expression of CLCA2 mRNA | CTD | PMID:22316170, PMID:32234424 | benzo[b]fluoranthene | increases expression | ISO | RGD:1552051 | 6480464 | benzo(b)fluoranthene results in increased expression of CLCA2 mRNA | CTD | PMID:26377693 | beta-damascenone | increases expression | ISO | RGD:1552051 | 6480464 | beta-damascenone results in increased expression of CLCA2 mRNA | CTD | PMID:22982537 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of CLCA2 mRNA | CTD | PMID:25181051 more ... | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of CLCA2 mRNA | CTD | PMID:26496021 | bisphenol A | increases methylation | ISO | RGD:1552051 | 6480464 | bisphenol A results in increased methylation of CLCA2 promoter | CTD | PMID:27312807 | cadmium atom | increases expression | ISO | RGD:1312594 | 6480464 | Cadmium results in increased expression of CLCA2 mRNA | CTD | PMID:21120746 | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of CLCA2 mRNA | CTD | PMID:25993096 | carbendazim | multiple interactions | EXP | | 6480464 | [carbendazim co-treated with 2, 5-hexanedione] results in decreased expression of CLCA2 mRNA | CTD | PMID:22382377 | carbon nanotube | increases expression | ISO | RGD:1552051 | 6480464 | Nanotubes more ... | CTD | PMID:25554681, PMID:25620056 | choline | multiple interactions | ISO | RGD:1552051 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CLCA2 mRNA | CTD | PMID:20938992 | cisplatin | increases expression | ISO | RGD:1312594 | 6480464 | Cisplatin results in increased expression of CLCA2 mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | RGD:1312594 | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of CLCA2 mRNA | CTD | PMID:27392435 | copper atom | multiple interactions | ISO | RGD:1552051 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLCA2 mRNA | CTD | PMID:15467011 | copper atom | increases expression | EXP | | 6480464 | Copper deficiency results in increased expression of CLCA2 mRNA | CTD | PMID:26033743 | copper(0) | multiple interactions | ISO | RGD:1552051 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLCA2 mRNA | CTD | PMID:15467011 | copper(0) | increases expression | EXP | | 6480464 | Copper deficiency results in increased expression of CLCA2 mRNA | CTD | PMID:26033743 | diarsenic trioxide | increases expression | ISO | RGD:1312594 | 6480464 | Arsenic Trioxide results in increased expression of CLCA2 mRNA | CTD | PMID:26705709 | dioxygen | increases expression | EXP | | 6480464 | Oxygen results in increased expression of CLCA2 mRNA | CTD | PMID:22911455 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of CLCA2 mRNA | CTD | PMID:29391264 | ethyl methanesulfonate | increases expression | ISO | RGD:1312594 | 6480464 | Ethyl Methanesulfonate results in increased expression of CLCA2 mRNA | CTD | PMID:23649840 | folic acid | multiple interactions | ISO | RGD:1552051 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CLCA2 mRNA | CTD | PMID:20938992 | fonofos | increases methylation | ISO | RGD:1312594 | 6480464 | Fonofos results in increased methylation of CLCA2 promoter | CTD | PMID:22847954 | formaldehyde | increases expression | ISO | RGD:1312594 | 6480464 | Formaldehyde results in increased expression of CLCA2 mRNA | CTD | PMID:23649840 | formaldehyde | decreases expression | ISO | RGD:1312594 | 6480464 | Formaldehyde results in decreased expression of CLCA2 mRNA | CTD | PMID:28937961 | furan | increases expression | EXP | | 6480464 | furan results in increased expression of CLCA2 mRNA | CTD | PMID:27387713 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of CLCA2 mRNA | CTD | PMID:33387578 | L-methionine | multiple interactions | ISO | RGD:1552051 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CLCA2 mRNA | CTD | PMID:20938992 | lucanthone | increases expression | ISO | RGD:1312594 | 6480464 | Lucanthone results in increased expression of CLCA2 mRNA | CTD | PMID:21148553 | methyl methanesulfonate | increases expression | ISO | RGD:1312594 | 6480464 | Methyl Methanesulfonate results in increased expression of CLCA2 mRNA | CTD | PMID:23649840 | nicotine | multiple interactions | ISO | RGD:1552051 | 6480464 | [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... | CTD | PMID:20230807 | paracetamol | affects expression | ISO | RGD:1552051 | 6480464 | Acetaminophen affects the expression of CLCA2 mRNA | CTD | PMID:17562736 | paracetamol | affects expression | EXP | | 6480464 | Acetaminophen affects the expression of CLCA2 mRNA | CTD | PMID:33387578 | parathion | increases methylation | ISO | RGD:1312594 | 6480464 | Parathion results in increased methylation of CLCA2 promoter | CTD | PMID:22847954 | perfluorohexanesulfonic acid | increases expression | ISO | RGD:1312594 | 6480464 | perfluorohexanesulfonic acid results in increased expression of CLCA2 mRNA | CTD | PMID:25812627 | perfluorooctanoic acid | increases expression | ISO | RGD:1312594 | 6480464 | perfluorooctanoic acid results in increased expression of CLCA2 mRNA | CTD | PMID:25812627 | pirinixic acid | decreases expression | ISO | RGD:1552051 | 6480464 | pirinixic acid results in decreased expression of CLCA2 mRNA | CTD | PMID:17426115 | sodium arsenite | increases expression | ISO | RGD:1312594 | 6480464 | sodium arsenite results in increased expression of CLCA2 mRNA | CTD | PMID:34032870 | sodium dichromate | decreases expression | EXP | | 6480464 | sodium bichromate results in decreased expression of CLCA2 mRNA | CTD | PMID:25993096 | terbufos | increases methylation | ISO | RGD:1312594 | 6480464 | terbufos results in increased methylation of CLCA2 promoter | CTD | PMID:22847954 | testosterone | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA2 mRNA | CTD | PMID:32741896 | titanium dioxide | increases expression | ISO | RGD:1552051 | 6480464 | titanium dioxide results in increased expression of CLCA2 mRNA | CTD | PMID:27760801 | trichloroethene | increases methylation | EXP | | 6480464 | Trichloroethylene results in increased methylation of CLCA2 gene | CTD | PMID:27618143 | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of CLCA2 mRNA | CTD | PMID:33387578 | triphenyl phosphate | decreases expression | EXP | | 6480464 | triphenyl phosphate results in decreased expression of CLCA2 mRNA | CTD | PMID:30589522 | triptonide | increases expression | ISO | RGD:1552051 | 6480464 | triptonide results in increased expression of CLCA2 mRNA | CTD | PMID:33045310 | zaragozic acid A | increases expression | EXP | | 6480464 | squalestatin 1 results in increased expression of CLCA2 mRNA | CTD | PMID:27225895 | zaragozic acid A | increases expression | ISO | RGD:1552051 | 6480464 | squalestatin 1 results in increased expression of CLCA2 mRNA | CTD | PMID:27225895 | |